Mu-opioid receptor agonists represent mainstays of pain management. However, the therapeutic use of these agents is associated with serious side effects, including potentially lethal respiratory depression. Accordingly, there is a longstanding interest in the development of new opioid analgesics with improved therapeutic profiles. The alkaloids of the Southeast Asian plant Mitragyna speciosa, represented by the prototypical member mitragynine, are an unusual class of opioid receptor modulators with distinct pharmacological properties. Here we describe the first receptor-level functional characterization of mitragynine and related natural alkaloids at the mu-, kappa-, and delta-opioid receptors. These results show that mitragynine and the oxidized analog 7-hydroxymitragynine, are partial agonists of the human mu-opioid receptor and competitive antagonists at the kappa- and delta-opioid receptors. We also show that mitragynine and 7-hydroxymitragynine are G-protein-biased agonists of the mu-opioid receptor, which do not recruit β-arrestin following receptor activation. Therefore, the Mitragyna alkaloid scaffold represents a novel framework for the development of functionally biased opioid modulators, which may exhibit improved therapeutic profiles. Also presented is an enantioselective total synthesis of both (-)-mitragynine and its unnatural enantiomer, (+)-mitragynine, employing a proline-catalyzed Mannich-Michael reaction sequence as the key transformation. Pharmacological evaluation of (+)-mitragynine revealed its much weaker opioid activity. Likewise, the intermediates and chemical transformations developed in the total synthesis allowed the elucidation of previously unexplored structure-activity relationships (SAR) within the Mitragyna scaffold. Molecular docking studies, in combination with the observed chemical SAR, suggest that Mitragyna alkaloids adopt a binding pose at the mu-opioid receptor that is distinct from that of classical opioids.
Mitragyna speciosa
, more commonly known as kratom,
is a plant native to Southeast Asia, the leaves of which have been
used traditionally as a stimulant, analgesic, and treatment for opioid
addiction. Recently, growing use of the plant in the United States
and concerns that kratom represents an uncontrolled drug with potential
abuse liability, have highlighted the need for more careful study
of its pharmacological activity. The major active alkaloid found in
kratom, mitragynine, has been reported to have opioid agonist and
analgesic activity in vitro and in animal models, consistent with
the purported effects of kratom leaf in humans. However, preliminary
research has provided some evidence that mitragynine and related compounds
may act as atypical opioid agonists, inducing therapeutic effects
such as analgesia, while limiting the negative side effects typical
of classical opioids. Here we report evidence that an active metabolite
plays an important role in mediating the analgesic effects of mitragynine.
We find that mitragynine is converted in vitro in both mouse and human
liver preparations to the much more potent mu-opioid receptor agonist
7-hydroxymitragynine and that this conversion is mediated by cytochrome
P450 3A isoforms. Further, we show that 7-hydroxymitragynine is formed
from mitragynine in mice and that brain concentrations of this metabolite
are sufficient to explain most or all of the opioid-receptor-mediated
analgesic activity of mitragynine. At the same time, mitragynine is
found in the brains of mice at very high concentrations relative to
its opioid receptor binding affinity, suggesting that it does not
directly activate opioid receptors. The results presented here provide
a metabolism-dependent mechanism for the analgesic effects of mitragynine
and clarify the importance of route of administration for determining
the activity of this compound. Further, they raise important questions
about the interpretation of existing data on mitragynine and highlight
critical areas for further research in animals and humans.
Depression is a debilitating chronic illness that affects around 350 million people worldwide. Current treatments, such as selective serotonin reuptake inhibitors, are not ideal because only a fraction of patients achieve remission. Tianeptine is an effective antidepressant with a previously unknown mechanism of action. We recently reported that tianeptine is a full agonist at the mu opioid receptor (MOR). Here we demonstrate that the acute and chronic antidepressant-like behavioral effects of tianeptine in mice require MOR. Interestingly, while tianeptine also produces many opiate-like behavioral effects such as analgesia and reward, it does not lead to tolerance or withdrawal. Furthermore, the primary metabolite of tianeptine (MC5), which has a longer half-life, mimics the behavioral effects of tianeptine in a MOR-dependent fashion. These results point to the possibility that MOR and its downstream signaling cascades may be novel targets for antidepressant drug development.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.